On the public record
Every politician on the site, every statement on file. Search, filter, and read the public record.
10,300+·quotes on file
I thank the gentleman from New York (Mr. Langworthy) for yielding the customary 30 minutes. Mr. Speaker, Republicans called us into an emergency meeting to consider today's rules several weeks ago. Several weeks ago, it is an emergency…
Let's go back to who caused this problem in the first place. It was those Republicans with their Republican tax cut. The Trump tax cut is the one that caused this problem. Let's not forget why we are facing this. Let's not forget, and…
I remind everybody here that Democrats offered an amendment in the Rules Committee so that we could have fixed the SALT problem not just for tax year 2023, which is when you pay your taxes now in 2024, but fixed it for 2 years. If…
Expanding access to nutrition programs in New Mexico is one of my top priorities.
When the most relevant patents expire on ELIQUIS, we will welcome generic competition.
we see a legacy portfolio of well-established products facing headwinds such as IRA.
Biosimilar competition is one way to drive down drug costs for patients and increase access.
I fully expect, and I will not try to stop a biosimilar IV version of KEYTRUDA coming on to the marketplace.
the IRA's real victim is innovation, and in turn, the millions of patients who are counting on the pharmaceutical industry to develop new therapies, will save lives, and improve health and well-being.
the IRA's real victim is innovation, and in turn, the millions of patients who are counting on the pharmaceutical industry to develop new therapies, will save lives, and improve health and well-being.
this portfolio--though the portfolio is declining, it is expected to continue to generate strong cash-flows to enable investment in our future growth drivers.
When the most relevant patents expire on ELIQUIS, we will welcome generic competition.
this portfolio--though the portfolio is declining, it is expected to continue to generate strong cash-flows to enable investment in our future growth drivers.
Biosimilar competition is one way to drive down drug costs for patients and increase access.
I anticipate that the price of STELARA will actually be lower in 2025.
we see a legacy portfolio of well-established products facing headwinds such as IRA.
I fully expect, and I will not try to stop a biosimilar IV version of KEYTRUDA coming on to the marketplace.
I anticipate that the price of STELARA will actually be lower in 2025.